Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
9.00
-0.15 (-1.64%)
Jul 29, 2026, 1:03 PM EDT - Market open
Xilio Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 150.33 | 137.53 | 55.29 | 44.7 | 120.39 | 198.05 |
Cash & Short-Term Investments | 150.33 | 137.53 | 55.29 | 44.7 | 120.39 | 198.05 |
Cash Growth | 68.77% | 148.74% | 23.68% | -62.87% | -39.22% | 929.49% |
Other Current Assets | 3.87 | 7.5 | 4.94 | 3.42 | 4.11 | 4.46 |
Total Current Assets | 154.21 | 145.03 | 60.23 | 48.13 | 124.5 | 202.52 |
Net Property, Plant & Equipment | 7.47 | 7.85 | 9.06 | 11.07 | 12.84 | 13.6 |
Other Long-Term Assets | 1.81 | 1.81 | 1.78 | 1.73 | 1.83 | 1.95 |
Total Assets | 163.49 | 154.69 | 71.08 | 60.93 | 139.17 | 218.06 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1.06 | 3.17 | 2.57 | 1.05 | 3.13 | 3.14 |
Accrued Expenses | 8.97 | 11.74 | 9.98 | 10.5 | 10.33 | 8.75 |
Current Portion of Long-Term Debt | - | - | - | 3.32 | 6.67 | 0.08 |
Current Portion of Leases | 1.38 | 1.34 | 1.19 | 1.05 | 0.92 | 0.8 |
Unearned Revenue | 31.54 | 40.02 | 13.52 | - | - | - |
Other Current Liabilities | - | - | - | 0.05 | 0.08 | 12.78 |
Total Current Liabilities | 42.96 | 56.27 | 27.26 | 15.96 | 21.12 | 12.78 |
Long-Term Debt | - | - | - | - | 3.17 | 9.63 |
Long-Term Leases | 5.25 | 5.61 | 6.95 | 8.14 | 9.19 | 10.11 |
Other Long-Term Liabilities | 42.73 | 57.53 | 19.26 | - | 0.05 | 0.12 |
Total Long-Term Liabilities | 47.98 | 63.14 | 26.22 | 8.14 | 12.4 | 19.85 |
Total Liabilities | 90.94 | 119.41 | 53.48 | 24.1 | 33.52 | 32.63 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | - | - | 0 | 0 | 0 |
Additional Paid-in Capital | 500.86 | 454.06 | 401.35 | 362.34 | 354.75 | 346.31 |
Retained Earnings | -428.32 | -418.79 | -383.75 | -325.51 | -249.11 | -160.89 |
Total Common Shareholders' Equity | 72.55 | 35.27 | 17.6 | 36.83 | 105.65 | 185.43 |
Shareholders' Equity | 72.55 | 35.27 | 17.6 | 36.83 | 105.65 | 185.43 |
Total Liabilities & Equity | 163.49 | 154.69 | 71.08 | 60.93 | 139.17 | 218.06 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 6.64 | 6.95 | 8.14 | 12.5 | 19.94 | 20.62 |
Net Cash (Debt) | 143.7 | 130.58 | 47.15 | 32.2 | 100.45 | 177.44 |
Net Cash Growth | 76.94% | 176.94% | 46.42% | -67.94% | -43.39% | - |
Net Cash Per Share | 12.40 | 15.62 | 12.34 | 16.39 | 51.34 | 443.09 |
Book Value | 72.55 | 35.27 | 17.6 | 36.83 | 105.65 | 185.43 |
Book Value Per Share | 6.26 | 4.22 | 4.60 | 18.75 | 54.00 | 463.05 |
Tangible Book Value | 72.55 | 35.27 | 17.6 | 36.83 | 105.65 | 185.43 |
Tangible Book Value Per Share | 6.26 | 4.22 | 4.60 | 18.75 | 54.00 | 463.05 |